XENEN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Balance Sheet & Cash RunwayA very low-leverage balance sheet and ~$1.2B in liquidity provide durable funding to complete NDA submission, support U.S. launch preparations and multiple late-stage trials. This reduces near-term refinancing risk and gives management optionality to execute commercialization and pipeline programs.
Durable Clinical EfficacyRobust long-term open-label outcomes signal sustained clinical benefit and patient retention potential, strengthening the product's value proposition to physicians and payers. Durable efficacy data lower clinical risk, support label claims and can enhance lifetime revenue durability if approved and adopted.
Broad Late-Stage Pipeline & Commercial BuildA diversified late-stage program across epilepsy, neuropsychiatry and pain plus ongoing commercial hiring reduces single-product binary risk and expands addressable markets. Parallel development and payer outreach increase the likelihood of orderly launch execution and multi-indication commercial scalability over time.
Bears Say
High Cash Burn & Negative Cash FlowExtremely large and persistent cash outflows mean the company remains dependent on its cash reserves and potential future financing. Sustained negative FCF can force dilutive raises or cutbacks if trials or commercialization costs accelerate, constraining strategic flexibility despite current liquidity.
No Meaningful Revenue & Widening LossesAbsence of recurring revenue and enlarging net losses mean the firm must rely on financing until product approval and commercialization. Widening losses reflect growing operating scale and compress the time to profitability, increasing long-term dilution and execution pressure on launches and post-approval performance.
Regulatory, Access & Competitive RiskEven with positive trials, FDA approval, reimbursement decisions and emerging Kv7 competitors create structural commercialization risk. Uncertain payer coverage and potential fast followers can limit realized price and market share, eroding projected returns on the clinical investment and lengthening time to breakeven.
Xenon News
XENEN FAQ
What was Xenon’s price range in the past 12 months?
Currently, no data Available
What is Xenon’s market cap?
Xenon’s market cap is $104.93B.
When is Xenon’s upcoming earnings report date?
Xenon’s upcoming earnings report date is Nov 11, 2026 which is in 94 days.
How were Xenon’s earnings last quarter?
Xenon released its earnings results on Aug 06, 2026. The company reported -$19.022 earnings per share for the quarter, beating the consensus estimate of -$19.553 by $0.531.
Is Xenon overvalued?
According to Wall Street analysts Xenon’s price is currently Undervalued.
Does Xenon pay dividends?
Xenon does not currently pay dividends.
What is Xenon’s EPS estimate?
Xenon’s EPS estimate is -19.45.
How many shares outstanding does Xenon have?
Currently, no data Available
What happened to Xenon’s price movement after its last earnings report?
Xenon reported an EPS of -$19.022 in its last earnings report, beating expectations of -$19.553. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Xenon?
Currently, no hedge funds are holding shares in MX:XENEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xenon Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,343.85 (― Upside)
$1,343.85 (― Upside)
Blogger Sentiment
Neutral
MX:XENEN Sentiment 50%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
110.96%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
86.58%
Trailing 12-Months
Company Description
Xenon
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
XENEN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple substantive positive developments: an imminent NDA submission supported by strong Phase 3 efficacy and compelling long-term open-label data, a healthy cash position ($1.2B) providing runway into 2029, advancing early-stage pain programs (including confirmed central exposure for Nav1.7) and active commercial build-out with encouraging HCP feedback. Key risks highlighted include the inherent uncertainty of regulatory review, pending readouts for MDD and pain PoC studies, ongoing payer/pricing discussions, common TEAEs that may affect tolerability at higher doses, and potential competition from future Kv7 entrants. On balance, the company's strengths (efficacy, safety dataset, cash runway, advancing pipeline and commercial preparations) outweigh the outstanding uncertainties and execution risks.View all MX:XENEN earnings summaries